{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:20:21Z","timestamp":1793992821423,"version":"4.8.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"State of Baden-W\u00fcrttemberg","award":["KKE Healthy Metabolism"],"award-info":[{"award-number":["KKE Healthy Metabolism"]}]},{"name":"State of Baden-W\u00fcrttemberg","award":["KKE Healthy Metabolism"],"award-info":[{"award-number":["KKE Healthy Metabolism"]}]},{"name":"State of Beden-W\u00fcrttemberg","award":["BW-ZDFP"],"award-info":[{"award-number":["BW-ZDFP"]}]},{"name":"State of Beden-W\u00fcrttemberg","award":["BW-ZDFP"],"award-info":[{"award-number":["BW-ZDFP"]}]},{"DOI":"10.13039\/501100010007","name":"Chinesisch-Deutsche Zentrum f\u00fcr Wissenschaftsf\u00f6rderung","doi-asserted-by":"publisher","award":["GZ-1546"],"award-info":[{"award-number":["GZ-1546"]}],"id":[{"id":"10.13039\/501100010007","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Small bowel adenocarcinoma (SBA) remains a rare malignancy accounting for less than 5% of all the gastrointestinal tract cancers. However, only limited data and expert guidelines are available for this entity. As a result, treatment concepts are predominantly derived from colorectal cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To substantiate data on the course of disease, diagnosis and treatment of SBA, we performed a population-based analysis from a Bavarian population of 2.2 million people.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 223 patients with SBA. Mean age at diagnosis was 67.8\u00a0years and patients were diagnosed rather late (34.5% UICC stage IV). Largest proportion of these patients were diagnosed with adenocarcinoma of the duodenum (132 patients, 59.2%) and most patients were diagnosed with late stage cancer, stage IV (70 patients, 31.4%). With respect to treatment, most patients underwent primary surgery (187 patients, 84.6%). Systemic therapy seemed to have an impact in UICC stage IV patients but not in UICC stage IIB or III. The 5-year survival rate was 29.0%. This was significantly less compared to colon cancer in the same cohort, which was 50.0%. Furthermore, median survival of patients with small bowel cancer was only 2.0\u00a0years (95% CI 1.4\u20132.5) compared to 4.9\u00a0years (95% CI 4.8\u20135.1) of patients with colon cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SBA showed a distinct epidemiology compared to colon cancer. Thus, data acquisition particularly on systemic treatment are paramount, with the objective to complement the available guidelines.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04344-z","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T16:04:28Z","timestamp":1664208268000},"page":"4579-4590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Characteristics and outcome of patients with small bowel adenocarcinoma (SBA)"],"prefix":"10.1007","volume":"149","author":[{"given":"Andreas","family":"Teufel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja M.","family":"Meindl-Beinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"H\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Roig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias P.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Scheiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Pauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Klinkhammer-Schalke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"4344_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.dld.2013.04.013","volume":"46","author":"T Aparicio","year":"2014","unstructured":"Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S et al (2014) Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis 46:97\u2013104","journal-title":"Dig Liver Dis"},{"key":"4344_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.6004\/jnccn.2019.0043","volume":"17","author":"AB Benson","year":"2019","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK et al (2019) Small bowel adenocarcinoma, version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 17:1109\u201333","journal-title":"J Natl Compr Canc Netw."},{"key":"4344_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cncr.20404","volume":"101","author":"BS Dabaja","year":"2004","unstructured":"Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J (2004) Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101:518\u2013526","journal-title":"Cancer"},{"key":"4344_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/cancers14061502","volume":"14","author":"P Di Nardo","year":"2022","unstructured":"Di Nardo P, Garattini SK, Torrisi E, Fanotto V, Miolo G, Buonadonna A et al (2022) Systemic treatments for advanced small bowel adenocarcinoma: a systematic review. Cancers (Basel). 14:1502","journal-title":"Cancers (Basel)."},{"key":"4344_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/212067","volume":"2008","author":"MH Farhat","year":"2008","unstructured":"Farhat MH, Shamseddine AI, Barada KA (2008) Small bowel tumors: clinical presentation, prognosis, and outcome in 33 patients in a tertiary care center. J Oncol 2008:212067","journal-title":"J Oncol"},{"key":"4344_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1634\/theoncologist.10-2-132","volume":"10","author":"MK Gibson","year":"2005","unstructured":"Gibson MK, Holcroft CA, Kvols LK, Haller D (2005) Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 10:132\u2013137","journal-title":"Oncologist"},{"key":"4344_CR7","first-page":"1121","volume":"33","author":"BI Gustafsson","year":"2008","unstructured":"Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M et al (2008) Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973\u20132004, and current diagnosis and therapy. Int J Oncol 33:1121\u20131131","journal-title":"Int J Oncol"},{"key":"4344_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/archsurg.142.3.229","volume":"142","author":"I Hatzaras","year":"2007","unstructured":"Hatzaras I, Palesty JA, Abir F, Sullivan P, Kozol RA, Dudrick SJ et al (2007) Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry. Arch Surg 142:229\u2013235","journal-title":"Arch Surg"},{"key":"4344_CR9","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3892\/ol.2017.6290","volume":"14","author":"M Hirao","year":"2017","unstructured":"Hirao M, Komori M, Nishida T, Iijima H, Yamaguchi S, Ishihara R et al (2017) Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: a multicenter retrospective cohort study by the Osaka Gut Forum. Oncol Lett 14:1628\u20131636","journal-title":"Oncol Lett"},{"key":"4344_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10147-017-1138-6","volume":"22","author":"T Horimatsu","year":"2017","unstructured":"Horimatsu T, Nakayama N, Moriwaki T, Hirashima Y, Fujita M, Asayama M et al (2017) A phase II study of 5-fluorouracil\/L-leucovorin\/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. Int J Clin Oncol 22:905\u2013912","journal-title":"Int J Clin Oncol"},{"key":"4344_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.dld.2017.09.123","volume":"50","author":"C Locher","year":"2018","unstructured":"Locher C, Batumona B, Afchain P, Carrere N, Samalin E, Cellier C et al (2018) Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 50:15\u201319","journal-title":"Dig Liver Dis"},{"key":"4344_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1590\/S1679-45082015AO3380","volume":"13","author":"I Negoi","year":"2015","unstructured":"Negoi I, Paun S, Hostiuc S, Stoica B, Tanase I, Negoi RI et al (2015) Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo) 13:500\u2013505","journal-title":"Einstein (Sao Paulo)"},{"key":"4344_CR13","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","volume":"27","author":"MJ Overman","year":"2009","unstructured":"Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS et al (2009) Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 27:2598\u20132603","journal-title":"J Clin Oncol"},{"key":"4344_CR14","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/bjc.2017.338","volume":"117","author":"H Sakae","year":"2017","unstructured":"Sakae H, Kanzaki H, Nasu J, Akimoto Y, Matsueda K, Yoshioka M et al (2017) The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer 117:1607\u20131613","journal-title":"Br J Cancer"},{"key":"4344_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","volume":"23","author":"XJ Xiang","year":"2012","unstructured":"Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F, Zhan ZY et al (2012) A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs 23:561\u2013566","journal-title":"Anticancer Drugs"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04344-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:08:57Z","timestamp":1689430137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04344-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4344"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04344-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"11 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}